Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Table. 2 First year treatment effects of first- and second line treatments

Variable	Empagliflozin + SoC [24, 25]	Sitagliptin + SoC [26]***	Liraglutide + SoC [27]	Basal Bolus [28]
HbA1c*	− 0.58	− 0.328	− 1.37	− 0.828
SBP*	− 3.9	− 0.62	− 1.82	0
DBP*	− 1.72	− 0.78	0.17	0
T-Chol*	7.81	3.56	0	0
HDL*	1.81	− 0.09	0	0
LDL*	4.79	1.42	0	0
TRIG*	0	0	0	0
BMI*	− 0.64	− 0.04	− 0.88	0.32
eGFR*	− 0.16	0.18	0	0
NSHE rate**	13.62	13.98	289.12	2566.83
SHE1 rate**	0.44	0.64	8.24	23.81
SHE2 rate**	0.06	0.14	1.10	3.19
GUI**	10.53	8.95	8.95***	–

BMI body mass index, DBP diastolic blood pressure, eGRF estimated glomerular filtration rate, GUI genital and urinary tract infection, HbA1c glycated hemoglobin, HDL high-density lipoprotein cholesterol, HR heart rate, LDL low-density lipoprotein cholesterol, NSHE non-severe hypoglycemic event, SBP systolic blood pressure, SHE severe hypoglycemic event, SoC standard of care, T-Chol total cholesterol, TRIG triglycerides
* Effect on the surrogate endpoints is applied on the first year of treatment
** Rate per 100 patient-year
*** Aside HbA1c effect, all other endpoints are assumed to be equal to placebo described in the EMPA-REG OUTCOME trial

ISSN: 1478-7547